This civil patent case was adjudicated by the United States District Court for the District of Delaware, a leading venue for U.S. patent disputes. All real‑world corporate identities are replaced with pseudonyms for confidentiality purposes. The plaintiff, Med‑Innovate Inc., is a U.S‑based medical equipment developer that owns multiple issued U.S. utility patents covering precision disposable sensor modules for home blood‑glucose monitoring devices. The patented technical solution optimizes signal collection and reduces measurement deviation, receiving FDA market clearance and occupying stable market share in North‑American consumer medical‑device channels. Med‑Innovate invested heavily in prototype testing, clinical verification and patent prosecution, and licensed its sensor technology to several mainstream medical‑device manufacturers.
The defendant structure contains two related entities. Nova‑Component Manufacturing Inc. is an overseas original‑equipment manufacturer responsible for mass‑producing sensor hardware. Apex Distribution LLC, a domestic limited‑liability shell company registered in Delaware with minimal declared capital, acted as the official U.S. importer and online sales operator. <b>The parent manufacturer Nova‑Component created Apex Distribution as an isolated‑risk shell entity; all import paperwork, e‑commerce store registrations and customer invoices bore only the shell‑company name, concealing the overseas manufacturer’s involvement from public records</b>. Without obtaining patent licenses from Med‑Innovate, Nova‑Component manufactured sensor modules reproducing every core technical feature of the asserted utility patents, and shipped finished goods to the United States under Apex Distribution’s import identity. Apex Distribution sold these patent‑infringing sensor accessories via major American e‑commerce platforms at substantially lower prices than the plaintiff’s authorized products.
Med‑Innovate purchased infringing products under notarized test‑buy procedures, collected shipping records, e‑commerce webpage evidence and supply‑chain metadata, and filed a patent‑infringement civil action under 35 U.S.C. §271. The plaintiff named both Apex Distribution and Nova‑Component as co‑defendants. The complaint alleged acts of importation, offer‑for‑sale and sale of infringing articles, and requested injunctive relief, compensatory damages, enhanced willful‑infringement damages and full recovery of reasonable attorney fees.
During litigation, the two defendants deployed separate defensive strategies. <b>Apex Distribution contended that it functioned merely as an import agent without substantive manufacturing capacity; it argued that the shell company should bear only limited liability, and that the overseas manufacturer should assume almost all legal responsibility</b>. Meanwhile, Nova‑Component argued that it conducted only overseas production outside United States territorial boundaries; it claimed that U.S. patent law did not regulate its foreign‑based manufacturing activities, and therefore it committed no direct infringement under U.S. patent statute. The defendants insisted that no joint‑infringement relationship existed between the two entities.
The district court carefully analysed joint‑infringement jurisprudence and the “direction‑and‑control” standard established by Federal Circuit precedent. <b>Under U.S. patent law, joint infringement arises when one party directs or controls every step of a patented method, or when multiple entities act together under a common business scheme to complete all elements of patent‑protected conduct</b>. Discovery evidence demonstrated that Nova‑Component fully controlled product design, mould parameters, production schedules and profit allocation. Apex Distribution had no independent product‑sourcing authority; it existed only to handle U.S. customs clearance and online sales for Nova‑Component, and shared sales revenue according to pre‑arranged internal agreements. The shell‑company structure was deliberately organised to attempt to isolate the parent manufacturer from U.S. patent‑litigation monetary risk.
<b>Foreign manufacturing alone does not escape U.S. patent liability, if the manufacturer directs and controls importation and domestic sales activities occurring within United States territory</b>. The court ruled that both defendants jointly and willfully infringed Med‑Innovate’s asserted utility patents. The judge rejected the shell‑company liability‑isolation argument, finding that Apex Distribution operated as the controlled domestic instrumentality of Nova‑Component. Considering the scale of infringing imports, sustained commercial sales volume, and defendants’ awareness of existing patent rights, the court awarded enhanced damages.
The final judgment ordered both defendants to cease importation, offer‑for‑sale and sale of infringing sensor modules within United States territory. <b>Joint‑and‑several liability applied: either defendant could be held responsible for satisfying the full damage award of USD 3.28 million, including compensatory damages, enhanced willful‑infringement damages and reasonable attorney‑litigation costs</b>. Even though Apex Distribution possessed limited assets, Nova‑Component, as the controlling parent entity, remained legally obligated to pay the complete judgment sum.
This Delaware‑district decision delivers practical lessons for global hardware suppliers entering the U.S. market. Creating thinly‑capitalized domestic shell companies cannot insulate overseas manufacturers from U.S. patent‑infringement liability when the parent directs core business decisions. Enterprises must conduct freedom‑to‑operate patent assessments before exporting technical products into the United States. Litigants should thoroughly investigate supply‑chain relationships during pre‑suit discovery, rather than only pursuing the visible domestic‑market shell entity listed on import documents.
1. https://www.courts.delaware.gov/ (United States District Court for the District of Delaware official portal)
2. https://www.uspto.gov/patents/laws (USPTO official overview of U.S. Patent Act Title 35)
3. https://www.federalcircuit.gov/opinions (U.S. Court of Appeals for the Federal Circuit case‑opinion database)
4. https://ipwatchdog.com/patent/joint‑infringement‑patent‑law‑overview/ (IPWatchdog analysis of U.S. patent joint‑infringement rules)
